Dec 17 () - Insmed said on Wednesday it had discontinued the development of its experimental anti-inflammatory drug to treat a chronic sinus condition after it failed to show benefit in a mid-stage ...
Stocktwits on MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit
Insmed subsequently decided to discontinue the program with immediate effect. ・The company also announced that it has ...
Insmed Inc. shares sunk in late trading Wednesday after the company said its drug to treat a sinus condition failed in a ...
TipRanks on MSN
Insmed halts CRSsNP program after Phase 2b failure
The latest announcement is out from Insmed ( (INSM) ).
Investing.com -- Insmed Inc (NASDAQ:INSM) stock tumbled 17.2% in after-hours trading Wednesday after the biopharmaceutical company announced its Phase 2b BiRCh study of brensocatib in patients with ...
Depemokimab has been approved by the MHRA as the first and only biologic with twice-yearly dosing to treat asthma and severe ...
The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results